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Abstract
Background The role of endothelin-1 (ET-1) and nitric
oxide (NO) as two important mediators in the development
of cerebral vasospasm (CVS) after subarachnoid haemor-
rhage (SAH) is controversial. The objective of this study
was to determine whether local levels of ET-1 and NO in
cerebral arterial plasma and/or in cerebrospinal fluid (CSF)
are associated with the occurrence of CVS after SAH.
Methods CVS was induced using the one-haemorrhage
rabbit model and confirmed by digital subtraction
angiography of the rabbits’ basilar artery on day 5. Prior
to sacrifice, local CSF and basilar arterial plasma
samples were obtained by a transclival approach to the
basilar artery. Systemic arterial plasma samples were
obtained. ET-1 levels were determined by immunometric
technique (pg/ml ± SEM) and total nitrate/nitrite level
spectrophotometrically (µmol/l ± SEM).
Findings Angiographic CVS was documented after SAH
induction (n=12, P<0.05). The ET-1 level in CSF was
significantly elevated by 27.3% to 0.84±0.08 pg/ml in SAH
animals (n=7) in comparison to controls (0.66±0.04 pg/ml,
n=7, P<0.05). There was no significant difference in ET-1
levels in systemic and basilar arterial plasma samples of
SAH animals compared to controls. A significant lack of
local NO metabolites was documented in basilar arterial
plasma after SAH (36.8±3.1 µmol/l, n=6) compared to
controls (61.8±6.2 µmol/l, n=6, P<0.01).
Conclusion This study demonstrates that an elevated ET-1
level in CSF and local lack of NO in the basilar arterial
plasma samples are associated with CVS after experimental
SAH.
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SEM standard error of the mean
DSA digital subtraction angiogram
CI of diff confidence intervals of difference
iNOS induced nitric oxide synthase
nNOS neuronal nitric oxide synthase
eNOS endothelial nitric oxide synthase
Introduction
Cerebral vasospasm (CVS) develops in 30–70% of patients
suffering from subarachnoid haemorrhage (SAH) [29] and
still remains an unsolved complication leading to cerebral
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ischaemia, permanent neurological dysfunction and death
[21]. Despite substantial progress in the understanding of
the development of CVS after SAH, its pathogenesis
remains unclear with regard to its complexity. In addition
to haemolytic metabolites recently discovered to be
pathogenetic factors, such as oxyhaemoglobin and bilirubin
oxidation products [4], the probably most important factors
contributing to the narrowing of cerebral arteries after SAH
are dysfunctions observed in the endothelin-1 (ET-1) and
nitric oxide (NO) system as a result of haemolytic processes
in the subarachnoid space [21].
ET-1 is the most potent vasoconstrictive endogenous
peptide produced by various cells, including endothelial
cells, smooth muscle cells, astrocytes and neurons [13].
In both experimental and clinical studies, elevated levels
of ET-1 in either cerebrospinal fluid (CSF) and/or
peripheral plasma have been observed to be associated
with the occurrence of CVS [9, 12, 35]; however, none of
the studies has focused on the local cerebral plasma levels
as the bridge between CSF and the periphery. The
therapeutic approach in affecting the system by selective
endothelin A receptor antagonism seems to be promising
according to preliminary clinical results [3, 31]. However,
ET-1’s source and cause of release remain unclear. Some
researchers propose that ET-1 is induced by cerebral
ischaemia and released from astrocytes, leading to
elevated levels in CSF [12, 22]. Others propose that
elevated ET-1 levels observed in peripheral plasma
samples are directly associated with CVS as a result of
endothelial dysfunction [9, 10].
Nitric oxide synthase mediates oxygen-dependent
conversion from l-arginine to radical NO, leading to
vasodilation through the cyclic guanylate monophosphate
pathway [2]. Decreased bioavailability of endogenous NO
has been widely accepted as an important part of the
pathogenesis of delayed CVS after SAH, more likely
caused by decreased production than by increased scav-
enging by haemolytic metabolites as was initially assumed
[21]. Controversies about the origin of decreased avail-
ability remain because of conflicting data published about
NO metabolite levels in the CSF and peripheral plasma [8,
21, 25].
On the basis of a novel sampling approach, our study
seeks to include local cerebral plasma levels as a further
variable to focus on for bridging a gap between conflicting
data published about CSF and peripheral plasma levels of
ET-1 and NO. With the use of an experimental SAH model,
it compares local basilar arterial plasma levels of ET-1 and
NO metabolites with those in CSF as well as compares
them to systemic arterial plasma levels. This may possibly
contribute to the clarification of conflicting data published




The protocol of this study was reviewed and approved by
the Swiss Institutional Animal Care and Use Committee
and meets the Swiss guidelines for laboratory animal use
(Canton Bern, Switzerland, approval no. 15/06).
Experimental groups
A total of 24 adult New Zealand white rabbits of either sex
weighing 2.6 to 3.6 kg were randomly assigned to two
groups (12 animals each). One group underwent experi-
mental SAH on day 0, and one served sham-operated as
control.
Angiography
After induction of general anaesthesia by intramuscular
administration of ketamine (30 mg/kg) and xylazine
(6 mg/kg), digital subtraction angiograms (DSA) were
performed on day 0 prior to SAH and on day 5 post
SAH. The rabbits’ left (day 0) or right (day 5) subclavian
artery was microsurgically cannulated using a 0.5-mm
plastic tube. The catheter was fixed distal to the vertebral
branch. Subsequently, DSA was performed by intraarte-
rial bolus injection of non-ionic iopamidol (0.6 ml/kg) as
contrast agent. Meanwhile, the arterial blood gas status
was analysed to monitor ventilation parameters from a
collected arterial blood sample. Images of the vertebro-
basilar system were obtained using a rapid sequential
angiographic technique with the small focal spot at
66 kV 125 mA (DFP 2000A, Toshiba Corporation®,
Japan). The average diameter of the basilar artery was
digitally calculated in μm using the automatic measure-
ment tool of ImagePro Discovery® analysis software
(MediaCybernetics, Bethesda, MD).
Cerebral vasospasm model
Following baseline DSA on day 0, the rabbits’ atlan-
tooccipital membrane was exposed by a microsurgical
posterior approach in prone position, and a 25-gauge
needle was inserted into the cerebromedullar cistern
while maintaining general anaesthesia. After relief of
1.0 ml CSF, an equal amount of unheparinised autolo-
gous arterial blood in the SAH group was injected into
the cistern under microscopic view to imitate SAH in
order to induce CVS. An equal amount of isotonic saline
solution instead was injected in controls. Postsurgical
pain relief was managed by subcutaneous administration
of buprenorphine (0.1–0.2 mg/kg).
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Collection of samples
Following post-treatment DSA on day 5, the rabbits
underwent coniotomy to keep up general anaesthesia by
inhalation of an isoflurane/oxygen/air mixture (2.5/5/
92.5 vol%). Systemic arterial plasma samples were
collected via the central arterial catheter. Basilar arterial
plasma and CSF samples were collected by a transclival
approach. In brief, the rabbits’ head was reclined and
fixed at a 20° angle, the trachea and oesophagus were
cautiously laterally retracted and the musculature under-
neath bluntly microsurgically dissected. The paraverte-
bral venous plexus exposed in the depth was coagulated
using a pair of bipolar forceps. The exposed dorsocaudal
edge of the clivus was followed frontocranially by cautious
dissection until the clivus’ surface on the base of the skull
could fully be displayed. A compression of the carotid
arteries and the descending vagus nerves was avoided
throughout the procedure.
An ellipsoid osteotomy (2-mm diameter) with the use
of a high-speed microdrill (Fine Science Tools, North
Vancouver, BC, Canada) exposed the dura and the
basilar artery underneath. The CSF sample was collected
by transdural insertion of a 26-gauge bent needle into
the subarachnoid space. The part of the dura exposed
was fully excised with microscissors in order to allow a
direct approach to the distal segment of the basilar
artery. The basilar arterial blood sample was collected
by intraluminal insertion of a 29-gauge bent needle into
the basilar artery. The collected blood samples were
centrifuged for 15 min at 1,500 rpm, and the plasma
remnants and CSF samples were stored at -80° C. The
animals were killed by intraarterial bolus injection of
sodium thiopenthal (40 mg/kg). All surgical procedures
were performed under sterile conditions.
In vitro
Detection of ET-1
In seven randomly chosen animals of each group, ET-1
systemic and basilar plasma levels as well as CSF levels
were quantitatively determined by the extraction-free
human ET-1 chemiluminescent sandwich immuno-
assay technique (QuantiGlo QET00B, R&D Systems,
Minneapolis, MN) as previously validated [18]. The
amino acid sequence of human ET-1 matches rabbit ET-
1 exactly. The quantitative range of the assay is 0.32 to
1,000 pg/ml. According to the manufacturer, cross-
reactions of antibodies used are observed for human
ET-1 (100%), human big ET-2 (0.01%), human big ET-
38 (0.019%), human ET-3 (7.8%) and human ET-2
(27.4%).
Measurement of NO metabolites
In six random animals of each group, nitrite/nitrate levels
were quantitatively determined as a relative measure for
basilar, systemic plasma and CSF levels of NO produc-
tion, as is common practice. Following reduction of
nitrate to nitrite with a modified Griess method, the total
nitrite level was spectrophotometrically detected at
540 nm (QuantiChrom Nitric Oxide Assay Kit, Bioassay
Systems, Hayward, CA) as previously validated [24].
Drugs
The following drugs were used: buprenorphinum (Temgesic®
0.3 mg/ml, Essex Chemie, Lucerne, Switzerland), iopamidol
(Iopamiro® 300 mg/ml, Bracco, Milan, Italy), isoflurane
(Forene® 99%, Abbott Laboratories, Abbott Park, IL),
ketamine HCl (Ketalar®50 mg/ml, Pfizer AG, Zurich,
Switzerland), sodium thiopenthalum (Pentothal® 25 mg/ml,
Abbott Laboratories, Abbott Park, IL) and xylazine HCl
(Xylapan® 20 mg/ml, Vetoquinol AG, Bern, Switzerland).
Statistical methods
Values are expressed as mean ± SEM (n=number of
animals). Statistical difference between two means and
multiple means was determined by Student's unpaired t-test
and one-way ANOVA followed by Bonferroni’s post-
testing, respectively. The statistical significance was
considered if the P-value was less than 0.05 (p<0.05) in
context of the 95% confidence intervals of the difference
examined (95% CI of diff).
Results
Arteriographic vasospasm
On day 5 after SAH, the diameter of the basilar artery was
significantly narrowed by 11.7% to 692.2 ± 23.0 µm (n=
12) compared to the animals’ baseline angiogram on day 0
(783.5 ± 25.1 µm, n=12, P<0.01, 95% CI of diff: 15.4 to
167.2 µm); on the same day, the basilar artery diameter
remained unchanged (778.5 ± 25.8 µm, n=12) in the
control group compared to the baseline on day 0 (787.2 ±
17.8 µm, n=12, P>0.05, 95% CI of diff: -84.6 to 67.2 µm)
(Fig. 1).
The animals’ initial blood pressure at baseline angiogra-
phy (SAH group: 71.1 ± 2.8 mmHg in mean arterial
pressure, n=12; controls: 68.8 ± 2.0 mmHg, n=12) was not
different from the values monitored on day 5 in both the
SAH group (70.6 ± 2.2 mmHg, n=12, P>0.05) and the
controls (70.8 ± 2.1 mmHg, n=12, P>0.05). Correspond-
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ingly, the initial blood gas parameters such as pO2 (SAH
group: 57.9 ± 3.6 mmHg; controls: 56.8 ± 2.1 mmHg),
pCO2 (SAH group: 50.6 ± 1.1 mmHg; controls: 50.1 ±
1.3 mmHg) and pH (SAH: 7.39 ± 0.01; controls: 7.38 ±
0.01) did not change compared to the values monitored
during follow-up angiography on day 5 in both the SAH
(P>0.05) and control group (P>0.05) and did not statisti-
cally differ between the two groups (P>0.05).
Local ET-1 levels
The ET-1 level in CSF samples was significantly elevated
by 27.3% to 0.84 ± 0.08 pg/ml in SAH animals (n=7) in
comparison to controls (0.66 ± 0.04 pg/ml, n=7, P<0.05,
95% CI of diff: 0.01 to .35 pg/ml). There was a slight
increasing tendency observed in plasma samples as well,
but no significant difference of ET-1 levels was remarked
in systemic or basilar arterial plasma samples of SAH
animals compared to controls. Local levels of ET-1 in the
basilar arterial plasma samples did not statistically differ
from those in the systemic plasma in SAH (n=7, P≥
0.05, 95% CI of diff: -0.12 to 0.53 pg/ml) or control
groups (n=7, P≥0.05, 95% CI of diff: -0.05 to 0.44 pg/ml),
nor did they statistically differ from those in CSF of the
SAH (P≥0.05, 95% CI of diff: -0.51 to 0.10 pg/ml) or
control groups (P≥0.05, 95% CI of diff: -0.51 to
0.09 pg/ml) (Fig. 2).
Local levels of NO metabolites
The level of total nitrate/nitrite in the basilar arterial
plasma samples was significantly reduced, by 40.4% to
36.8 ± 3.1 µmol/l in SAH animals (n=6) compared to
controls (61.8 ± 6.2 µmol/L, n=6, P<0.01, 95% CI of
diff: 9.5 to 40.3 µmol/l). A slightly decreasing tendency
of the local NO metabolite level was also observed in
CSF (n=6) and systemic arterial plasma (n=6) samples
in comparison to the controls (n=6), but remained
insignificant (P>0.05). The local level of total nitrate/
nitrite in basilar arterial plasma samples did not differ
statistically from the level in systemic samples for both
the SAH group (n=6, P>0.05) and the control group (n=
6, P>0.05). It was significantly higher than the level
detected in CSF samples for both the SAH group (n=6,
P<0.001, 95% CI of diff: 15.9 to 37.1 µmol/l) and the
control group (n=6, P<0.001, 95% CI of diff: 28.5 to
62.7 µmol/l) (Fig. 3).
Fig. 2 Box plot with SAH vs. control: ET-1 levels in CSF, basilar and
systemic arterial plasma on day 5 after SAH (in pg/ml statistically
differ SEM). (*P<0.05; ns=non-significant)
Fig. 3 Box plot with SAH vs. control: total nitrite levels in CSF,
basilar and systemic arterial plasma on day 5 after SAH (in µmol/l +/-
SEM). (*P<0.01)
Fig. 1 Box plot with the absolute change of the basilar artery in
diameter: Baseline angiography in SAH and control group on day 0
vs. on day 5 (in µm ± SEM). (*P<0.05; ns=non-significant)
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Discussion
Origin of increased bioavailability of ET-1
ET-1 is produced by various cells, including neurons, glial
cells, smooth muscle cells and endothelial cells, within
minutes after being stimulated by hypoxia, ischaemia and
shear stress [13]. Its release from vascular endothelial and
smooth muscle cells is more likely to follow a paracrine
than an endocrine pattern, as ET-1 abluminally binds to
ETA receptors in the smooth muscle cell layer to mediate
long-lasting vasoconstriction [13, 32]. Despite broad
acceptance of ET-1 as a contributing mediator of CVS,
conflicting data have been reported about the correlation of
ET-1’s plasma level and CVS. On one hand, ET-1’s
peripheral plasma level has been found to correlate with
the severity of vascular diseases [13], as shown in clinical
studies of Juvela et al. [9, 10] and Suzuki et al. [30] in
regard to the occurrence of delayed cerebral ischaemia and
vasospasm after SAH. On the contrary, other authors were
not able to correlate ET-1 plasma levels to CVS [11, 12,
27].
In our experimental study neither the local ET-1 level in
the basilar arterial nor the one in systemic plasma samples
after SAH differed significantly from those in controls.
These findings support the clinical observations reported
elsewhere [11, 12, 27]. In addition, our data did not show
significant differences between the local ET-1 level
obtained from basilar arterial plasma samples compared to
the systemic samples within either the SAH or the control
group. Nevertheless, our results demonstrated a trend
towards lower levels of this peptide in the basilar arterial
samples than in the peripheral plasma in both groups. This
observation might suggest that the elevated peripheral
plasma levels of ET-1 observed in clinical studies are rather
unlikely to be caused by increased release of ET-1 into the
cerebral circulation [9, 10, 30]. One reason might be that
the systemic plasma ET-1 concentration could be signifi-
cantly influenced by physiological and pathological
conditions in structures other than the brain and cerebral
vessels, as shown, for example, in systemic hypertension
and heart failure [13, 35].
Instead, our data demonstrated a significantly elevated
ET-1 level in CSF on day 5 after experimental SAH. This
observation supports the hypothesis of mediated CVS
partly due to elevated ET-1 levels in CSF. In experimental
studies on felines and canines, intracisternal bolus injec-
tions of ET-1 have previously demonstrated ET-1’s potency
in mediating vasoconstriction from the abluminal site [16].
Pluta et al.’s experimental study in primates found the ET-1
level in CSF to be dependent on astrocyte release [22]. Our
finding of an elevated level of ET-1 in CSF confirms the
clinical results reported earlier [11, 12, 14, 27, 28]. Among
these reports the correlation of the CSF to the plasma levels
of ET-1 in SAH-induced CVS is still controversial. With
respect to the apparently very limited specificity and
sensitivity of ET-1 in systemic plasma to correlate with
CVS, some authors showed ET-1’s peripheral plasma
concentration during CVS to act differently from the one
in CSF [12, 27], while Kastner et al. demonstrated them to
be relatively similar in concentration averaged over time
[11]. Keeping in mind that ET-1 levels of local cerebral
plasma and CSF had not been previously examined, we
documented the basilar arterial plasma levels of ET-1 to be
statistically indifferent from the ones in CSF. These
findings might possibly be explained epiphenomenally
due to the ET-1 conversion rate in the endothelial basilar
arterial layer or due to ET-1 release from the CSF into
the cerebral circulation. This hypothesis might also be
supported by Menon et al. who found high arterio-
jugularvenous ET-1 gradients in patients suffering from
SAH-induced CVS [15].
Though our study results tend to agree with these
hypotheses, one needs to keep in mind that the SAH model
used in this study is certainly limited in mimicking the
complex clinical conditions of an aneurysmal SAH in
humans. Due to single time point assessment during the
peak time of CVS, the study is also limited in providing
data about possible metabolite level changes during the
development of CVS.
Origin of reduced NO bioavailability
Endogenous NO is a radical product of the oxidation of
l-arginine to citrulline by nitric oxide synthase, which
causes vasodilation through activation of the soluble
guanylate cyclase pathway. Three isoenzyme forms are
known to play a role in vasculature-mediating NO
release: induced nitric oxide synthase (iNOS), periadven-
titial neuronal nitric oxide synthase (nNOS) and endo-
thelial nitric oxide synthase (eNOS). While iNOS
possibly plays a pathophysiological role in the acute
and early states after SAH, there is debate over whether
the activity of nNOS and eNOS has a role in the delayed
development of CVS after SAH [5, 21]. After a short
half-life, radical NO is metabolised by being oxidised to
stable nitrite and nitrate. This serves as an acceptable
relative measure of NO level in both experimental and
clinical research. Decreased bioavailability of NO has
been shown to be associated with the development of
delayed CVS after SAH, more likely caused by deprived
production rather than just increased scavenging by
haemolytic metabolites such as oxyhaemoglobin as ini-
tially assumed [5, 21].
This study demonstrated the novel finding that locally
reduced NO availability in basilar arterial plasma is
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associated with CVS after SAH. It hypothesises that there is
decreased production of NO in the endothelial layer of local
cerebral vasculature. This local lack of NO in the basilar
plasma might hypothetically be explained by dysfunctional
endothelium [7] or by inhibited enzyme activity of eNOS
[8]. Whether these results are caused by downregulation of
eNOS expression itsself, however, remains uncertain
because of the conflicting data reported: Hino et al. [6]
found decreased eNOS mRNA in cerebral arteries of
primates and Park et al. [20] in the microvasculature of
rats after induced SAH. On the contrary, Vatter et al. could
recently not reproduce those findings by histochemical
staining of eNOS in the rats’ basilar artery after SAH [33].
In support of our hypothesis, Jung et al. found that the level
of asymmetric dimethylarginine, an endogenous competi-
tive inhibitor of nitric oxide synthase and a metabolisation
product of bilirubin, was elevated in CSF during delayed
CVS in an experimental primate model [8]. It is suggested
to contribute to the endogenous inhibition of eNOS [8] and,
thus, possibly to the lack of NO in the basilar arterial
plasma found in our study.
Uncertainty remains about conflicting data reported for
NO metabolites after SAH concerning the CSF level. While
some authors reported in clinical studies with small sample
sizes that NO metabolite levels in CSF were increased after
SAH [17, 25, 29, 34]; others observed CVS to be
associated with reduced CSF levels of nitrite [26], suggest-
ing possible affection of nNOS [8, 23]. However, our data
do not confirm any significant change in nitrite level in
CSF in either direction. Possible explanations for the
conflicting data published are a lack of large clinical
sample sizes, different time courses, and different spots of
vessel catheterisation and sample collection.
Our data also do not demonstrate a significant difference
between nitrite levels in systemic plasma after SAH
compared to controls, in agreement with clinical data
provided by Suzuki et al. [29]. It suggests that systemic
plasma may be too unspecific to detect a locally limited
pathophysiological process in the cerebrovascular NO
system.
Interaction of ET-1 and NO
Experimental data have been published suggesting that
there may be a direct or indirect interaction between the
ET-1 and NO systems on the basis of a yet unclear
mechanism. Ohkita et al. provided evidence for inhibi-
tion of ET-1 production by NO, assuming a modulatory
role of NO [19]. Impairment of this possible modulatory
role of NO on ET-1 during CVS after SAH has been found
by Alabadi et al. [1] and supports our observation that an
elevated ET-1 level in CSF accompanies a lack of local
NO.
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Comments
The authors used a well established animal model (rabbit single
hemorrhage) of cerebral vasospasm (CVS) with the aim to
investigate the source of ET-1 and NO in the development of
CVS. They determined levels of ET-1 and nitrite in the basilar
artery (BA), the systemic plasma and the CSF. They observed an
increased level of ET-1 in the CSF after experimental SAH but no
changes in the BA and the systemic circulation. For nitrate they
found decreased levels in the BA after SAH but no changes in
the systemic circulation and the CSF.
The investigation is well performed, the data is presented in an
adequate and clear form. It supports the pathophysiological concept,
that for the development of CVS relevant changes of the ET
metabolismn are localiced inside the cereborspinal space but not in
the systemic circulation. Furthermore, the present data support a
decreased function of the NO metabilism mainly inside the cerebro-
vasculature after SAH, which represents another factor for the
development of CVS.
Harmut Vatter
Dept. of Neurosurgery, Goethe-University
Frankfurt am Main, Germany
It has been more than 50 years since delayed cerebral vasospasm in
patients after aneursymal subarachnoid hemorrhage (aSAH) has been
linked to a poor outcome.[1] Most unfortunate is that this rather
uncommon but most devastating form of stroke affects those patients
who have already been treated by surgical or endovascular securing of
the aneurysm. In extensive worldwide research, thousands of neuro-
surgeons and scientists have examined innumerable chemicals and
drugs using simple, sophisticated and ingenious in vivo and in vitro
models testing numerous hypotheses hoping to cure or prevent
delayed cerebral vasospasm. Still, it is an effort in vain with regard
to finding the magic bullet but because of this effort, we have
significantly advanced our knowledge of cerebral vessels physiology
and developed a better understanding of the pathophysiological
changes in the brain and the cerebral vessels evoked by aSAH. In
spite of these advances, there appears to be an increasing uneasiness
that the failure to find treatment may be due to a “barking up the
wrong tree”.[2]
The discoveries that nitric oxide (NO), a toxic gas from fumes of
gasoline engines is Furchgott’s endothelium-derived relaxing factor
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(EDRF),[3] that endothelin-1 (ET-1), a venom from the sarafotoxin
family, is produced in our bodies by endothelial cells as the most
potent vasoconstrictor[4] and that both regulate cerebral blood have
given new hope to develop a cure for vasospasm.
In the 1990s, numerous studies suggested that NO or ET-1 was
involved in the development of delayed cerebral vasospasm,[5, 6]
while other reports denied such a relationship.[7, 8] The controversy is
still ongoing although preclinical and clinical trials using intracarotid
infusion of NO gas solution,[9] intracarotid or intrathecal administra-
tion of NO donors[10-12] and ET-1 receptor inhibitors have claimed
clinical success.[13, 14]
However, better understanding of aSAH pathophysiology, discovery
of new aSAHrelated events like cortical spreading ischemia[15] and,
probably most importantly, the failure of Clazosentan, a selective ET-1 A
receptor inhibitor, in Phase II clinical study[2] to improve the outcome
despite prevention of vasospasm all lead to a paradigm shift with the focus
on the possibility that a stroke after aSAH may be evoked by another
nonvasospasm-related mechanism(s). Growing body of evidence suggests
that these pathomechanisms are a result of the presence of an arterial blood
clot in the subarachnoid space, increased ET-1 in CSF, and decreased
availability of NO in cerebral arteries.[2, 15]
In their clever, well-planned and executed, but most confirmatory
in vivo experimental study published in this issue of Acta Neuro-
chirugica , V. Neuschmelting and colleagues simultaneously examined
the role of both NO and ET-1 in the development of vasospasm in a
rabbit model of aSAH. To assure the relevance of their findings, the
authors used an innovative surgical approach. They collected blood
samples directly from the basilar artery to compare to the peripheral
arterial blood and CSF samples. The authors convincingly showed that
the presence of ET-1 in the CSF and endothelial NOS dysfunction
were associated with vasospasm development. These findings, while
not altogether new,[6, 10, 11, 13, 14] are a novel approach to sample
collection and shed new light on the pathophysiology of vasospasm
after SAH by separating the extra- and intravascular events. Doing this
further opens the door to a Kuhnian revolution in our understanding
the role of vasospasm in stroke after aSAH and hopefully leads to
successful treatment of this dreadful complication of a ruptured
intracranial aneurysm.
Ryszard M. Pluta
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD, USA
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